Bruce D. Jackson
Stock Analyst at Benchmark
(2.53)
# 2,268
Out of 5,147 analysts
10
Total ratings
55.56%
Success rate
17.43%
Average return
Main Sectors:
Stocks Rated by Bruce D. Jackson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HUMA Humacyte | Maintains: Buy | $11 → $10 | $1.12 | +796.86% | 2 | Jan 21, 2026 | |
| EXAS Exact Sciences | Downgrades: Hold | n/a | $103.38 | - | 2 | Nov 24, 2025 | |
| MLSS Milestone Scientific | Maintains: Speculative Buy | $1.25 → $1 | $0.26 | +277.93% | 1 | Nov 20, 2025 | |
| BLTE Belite Bio | Maintains: Buy | $80 → $132 | $190.30 | -30.64% | 1 | Oct 31, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Maintains: Speculative Buy | $14 → $7 | $0.21 | +3,160.36% | 1 | Sep 15, 2025 | |
| UNCY Unicycive Therapeutics | Maintains: Speculative Buy | $3 → $21 | $6.93 | +203.03% | 1 | Sep 15, 2025 | |
| HBIO Harvard Bioscience | Maintains: Speculative Buy | $3 → $2 | $0.61 | +225.89% | 1 | Sep 10, 2025 | |
| CLNN Clene | Maintains: Buy | $33 → $31 | $5.23 | +493.30% | 1 | Sep 10, 2025 |
Humacyte
Jan 21, 2026
Maintains: Buy
Price Target: $11 → $10
Current: $1.12
Upside: +796.86%
Exact Sciences
Nov 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $103.38
Upside: -
Milestone Scientific
Nov 20, 2025
Maintains: Speculative Buy
Price Target: $1.25 → $1
Current: $0.26
Upside: +277.93%
Belite Bio
Oct 31, 2025
Maintains: Buy
Price Target: $80 → $132
Current: $190.30
Upside: -30.64%
Reviva Pharmaceuticals Holdings
Sep 15, 2025
Maintains: Speculative Buy
Price Target: $14 → $7
Current: $0.21
Upside: +3,160.36%
Unicycive Therapeutics
Sep 15, 2025
Maintains: Speculative Buy
Price Target: $3 → $21
Current: $6.93
Upside: +203.03%
Harvard Bioscience
Sep 10, 2025
Maintains: Speculative Buy
Price Target: $3 → $2
Current: $0.61
Upside: +225.89%
Clene
Sep 10, 2025
Maintains: Buy
Price Target: $33 → $31
Current: $5.23
Upside: +493.30%